CONCISE REPORT

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

S Takahashi, Y Moriwaki, T Yamamoto, Z Tsutsumi, T Ka, M Fukuchi

Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1–1, Nishinomiya, Hyogo 663–8501, Japan

Correspondence to:
Correspondence to:
Dr Y Moriwaki;
t-ohk{at}hyo-med.ac.jp

Objective: To assess the effect of a combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism in hypertriglyceridaemic and/or hypertensive patients with gout.

Methods: Twenty seven patients with gout were included in a fenofibrate plus anti-hyperuricaemic agents combination study, and 25 in a losartan plus anti-hyperuricaemic agents combination study. Serum uric acid concentration, uric acid clearance, and 24 hour urinary uric acid excretion were measured before and two months after the addition of fenofibrate (300 mg once daily) or losartan (50 mg once daily) to anti-hyperuricaemic agents.

Results: Combination therapy of fenofibrate or losartan with anti-hyperuricaemic agents, which included benzbromarone (50 mg once daily) or allopurinol (200 mg twice a day), significantly reduced serum uric acid concentrations in accordance with increased uric acid excretion.

Conclusion: A combination of fenofibrate or losartan with anti-hyperuricaemic agents is a good option for the treatment of gout patients with hypertriglyceridaemia and/or hypertension, though the additional hypouricaemic effect may be modest.

Keywords: losartan; fenofibrate; uric acid; hypertension; hypertriglyceridaemia

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Wall, G. C., Cooper, S. A. (2009). Gout and Hyperuricemia: New Guidelines and Treatments. Journal of Pharmacy Practice 22: 104-115 [Abstract]  
• Zhang, W, Doherty, M, Bardin, T, Pascual, E, Barskova, V, Conaghan, P, Gerster, J, Jacobs, J, Leeb, B, Liote, F, McCarthy, G, Netter, P, Nuki, G, Perez-Ruiz, F, Pignone, A, Pimentao, J, Punzi, L, Roddy, E, Uhlig, T, Zimmermann-Gorska, I (2006). EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1312-1324 [Abstract] [Full Text]  
• Choi, H. K., Mount, D. B., Reginato, A. M. (2005). Pathogenesis of Gout. ANN INTERN MED 143: 499-516 [Full Text]  
• Suresh, E (2005). Diagnosis and management of gout: a rational approach. Postgrad. Med. J. 81: 572-579 [Abstract] [Full Text]  
• Hepburn, A. L., Feher, M. D., Terkeltaub, R. A. (2004). Gout. NEJM 350: 519-520 [Full Text]